U.S. FDA Says Agency Hasn’t Approved Ranbaxy’s Generic Lipitor
The Food and Drug Administration hasn’t approved Ranbaxy Laboratories Ltd. (RBXY)’s generic version of Pfizer Inc. (PFE)’s $10.7 billion Lipitor cholesterol pill, Sandy Walsh, a spokeswoman for the agency, said.
An FDA vendor made a mistake and a statement from the agency announcing the approval of Ranbaxy’s generic drug was distributed in error, Walsh said in an e-mail.
To contact the editor responsible for this story: Adriel Bettelheim at firstname.lastname@example.org.
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.